Delivery Order SPE2DB20D7066-SPE2DB25FC4LC
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order valued at $18,788.88 to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules (100-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,918.73. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a ceiling value of $4,284.71. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The award was competitively procured with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) with a contract value of $6,400.76. This competitively awarded, firm fixed price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Vyvanse 70 mg capsules (100-count units) valued at $3,496.33 with a firm fixed price structure. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $7,598.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units). This is a non-set-aside competitive award with performance completion scheduled for July 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location. This delivery order represents a child contract executed under...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4LCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $13,377.00 under a firm fixed-price contract structure. This competitively awarded, non-set-aside delivery order is scheduled for completion by August 22, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a broad portfolio of medications and medical supplies to support military and veteran healthcare systems. The company's extensive federal contract awards with the Defense Logistics Agency demonstrate its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains. This delivery order for Vyvanse, a central nervous system stimulant used in ADHD treatment, exemplifies the company's role in providing specialty medications essential to military medical readiness and personnel healthcare management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 8/21/25 |